2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 602

Comparison of Men and Women with Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 433

Comparison of PROMIS Computerized Adaptive Testing-Administered Item Banks versus Fixed Short Forms in Juvenile Myositis

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 688

Comparison of the Physicians’ Clinical Diagnosis and the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Multiethnic Cohort

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 669

Complement Activation in Probable Systemic Lupus Erythematosus (pSLE) May Predict Progression to SLE Defined by Fulfillment of ACR Classification Criteria

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 642

Complement Deposition C4d on Platelets Is Associated with Vascular Events in Systemic Lupus Erythematosus

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 787

Complement Protein Levels Reflect Disease Activity in Juvenile Idiopathic Arthritis

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Abstract Number: 323

Compliance with Hydroxychloroquine Dosage According to 2016 American Academy of Ophthalmology (AAO) Guidelines: A Study with 6591 Patients

Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

9:00AM-11:00AM: Abstract Number: 243

Concomitant Fibromyalgia in Patients with Other Rheumatic Diseases and Response to Treatment

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 429

Concordance Between Physician and Patient Assessment of Disease Activity in Rheumatoid Arthritis Using Disease Activity Score: Phase II Results

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 464

Continuous Decrease in Serum RF Titer During Anti-TNF Therapy Was Associated with Suppression in Progression of RA Joint Damage

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 417

Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 223

Correlation Between Heart Rate Variability Parameters and Circulating Neuropeptides in Fibromyalgia

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 427

Correlation Between Patient Reported Outcomes Measurement Information System (PROMIS) and RAPID3 in Rheumatoid Arthritis Patients Starting a New Biologic DMARD

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 682

Correlation Between the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) and Health-Related Quality of Life (HRQoL) and Other PROs in a Primarily Mestizo Population

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 692

Correlation of Urinary Soluble CD163 Levels with Clinicopathological Features in Lupus Nephritis: Its Role as a Potential Biomarker

SLE – Clinical Poster I: Epidemiology & Pathogenesis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].